Business Description
cbdMD Inc
NAICS : 325412
SIC : 2834
ISIN : US12482W4087
Total Employee Number:
42Description
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.36 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.43 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -17.72 | |||||
Beneish M-Score | -1.93 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -71.8 | |||||
3-Year EBITDA Growth Rate | 89.8 | |||||
3-Year EPS without NRI Growth Rate | 79.5 | |||||
3-Year FCF Growth Rate | 83.7 | |||||
3-Year Book Growth Rate | -83.7 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.74 | |||||
9-Day RSI | 47.22 | |||||
14-Day RSI | 45.2 | |||||
3-1 Month Momentum % | 0.38 | |||||
6-1 Month Momentum % | -54.76 | |||||
12-1 Month Momentum % | -13.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.82 | |||||
Quick Ratio | 1.71 | |||||
Cash Ratio | 0.89 | |||||
Days Inventory | 130.33 | |||||
Days Sales Outstanding | 21.01 | |||||
Days Payable | 53.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -275.1 | |||||
Shareholder Yield % | 18.5 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 59.38 | |||||
Operating Margin % | -13.4 | |||||
Net Margin % | -13.29 | |||||
EBITDA Margin % | -4.79 | |||||
FCF Margin % | -13.28 | |||||
OCF Margin % | -12.41 | |||||
ROE % | -41.12 | |||||
ROA % | -24.02 | |||||
ROIC % | -40.53 | |||||
3-Year ROIIC % | -66.66 | |||||
ROC (Joel Greenblatt) % | -89.21 | |||||
ROCE % | -40.7 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.29 | |||||
PB Ratio | 0.79 | |||||
Price-to-Tangible-Book | 1.05 | |||||
EV-to-EBIT | -1.9 | |||||
EV-to-EBITDA | -5.3 | |||||
EV-to-Revenue | 0.25 | |||||
EV-to-Forward-Revenue | 0.98 | |||||
EV-to-FCF | -1.91 | |||||
Price-to-GF-Value | 4.34 | |||||
| Price-to-Net-Current-Asset-Value | 1.34 | |||||
Earnings Yield (Greenblatt) % | -52.63 | |||||
FCF Yield % | -36.38 |
cbdMD Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
cbdMD Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2026-12-18 | In 174 days | ||
| Third quarter earnings conference call for 2026 | 2026-08-14 16:20 | In 49 days | ||
| Third quarter earnings results for 2026 | 2026-08-14 | In 48 days | ||
| Second quarter earnings conference call for 2026 | 2026-05-14 16:20 | 0.80 (+3.57%) | ||
| Second quarter earnings results for 2026 | 2026-05-14 | 0.80 (+3.57%) | ||
| General meeting for 2026 | 2026-03-30 11:00 | 0.72 (-1.65%) | ||
| First quarter earnings conference call for 2026 | 2026-02-17 16:20 | 0.70 (+2.36%) | ||
| First quarter earnings results for 2026 | 2026-02-17 | 0.70 (+2.36%) | ||
| Fourth quarter earnings conference call for 2025 | 2025-12-19 16:20 | 1.93 (-11.87%) | ||
| Annual report for 2025 | 2025-12-19 | 1.93 (-11.87%) |
Show
Entries
Guru Commentaries on AMEX:YCBD
No articles.
Press Release
Articles on cbdMD Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers